BMEA vs. EPZM, CHMA, PRTK, CTIC, KURA, TARO, GMTX, DVAX, SUPN, and LGND
Should you be buying Biomea Fusion stock or one of its competitors? The main competitors of Biomea Fusion include Epizyme (EPZM), Chiasma (CHMA), Paratek Pharmaceuticals (PRTK), CTI BioPharma (CTIC), Kura Oncology (KURA), Taro Pharmaceutical Industries (TARO), Gemini Therapeutics (GMTX), Dynavax Technologies (DVAX), Supernus Pharmaceuticals (SUPN), and Ligand Pharmaceuticals (LGND). These companies are all part of the "medical" sector.
Biomea Fusion (NASDAQ:BMEA) and Epizyme (NASDAQ:EPZM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability, institutional ownership and community ranking.
Biomea Fusion currently has a consensus target price of $28.25, suggesting a potential upside of 582.37%. Given Biomea Fusion's higher probable upside, analysts clearly believe Biomea Fusion is more favorable than Epizyme.
Epizyme received 440 more outperform votes than Biomea Fusion when rated by MarketBeat users. Likewise, 62.19% of users gave Epizyme an outperform vote while only 61.67% of users gave Biomea Fusion an outperform vote.
96.7% of Biomea Fusion shares are held by institutional investors. Comparatively, 76.5% of Epizyme shares are held by institutional investors. 27.6% of Biomea Fusion shares are held by insiders. Comparatively, 23.4% of Epizyme shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Biomea Fusion has a net margin of 0.00% compared to Epizyme's net margin of -391.90%. Biomea Fusion's return on equity of -69.88% beat Epizyme's return on equity.
Biomea Fusion has a beta of -0.35, indicating that its share price is 135% less volatile than the S&P 500. Comparatively, Epizyme has a beta of -0.41, indicating that its share price is 141% less volatile than the S&P 500.
In the previous week, Biomea Fusion had 12 more articles in the media than Epizyme. MarketBeat recorded 12 mentions for Biomea Fusion and 0 mentions for Epizyme. Epizyme's average media sentiment score of 0.22 beat Biomea Fusion's score of -0.33 indicating that Epizyme is being referred to more favorably in the news media.
Biomea Fusion has higher earnings, but lower revenue than Epizyme. Biomea Fusion is trading at a lower price-to-earnings ratio than Epizyme, indicating that it is currently the more affordable of the two stocks.
Summary
Biomea Fusion beats Epizyme on 10 of the 16 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding BMEA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biomea Fusion Competitors List
Related Companies and Tools
